People | June 17, 2022
Valo Therapeutics appoints Hemanshu Shah as Chief Business Officer
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Acceptance based on results from the phase 3 KEYNOTE-091 trial
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Amarex Clinical Research guides its client to phase II of FDA trials
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Bayer now present in four of the largest biotechnology hubs in the United States
Subscribe To Our Newsletter & Stay Updated
